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Abstract: Background: Dietary polyphenols, including flavonoids, have been the focus of major
recent attentions due to their wide content in a variety of foods commonly consumed and the findings
from numerous studies showing evidence of an association with positive outcomes on human health.
Methods: A systematic search using electronic databases PubMed and EMBASE was performed
to retrieve English language studies published from the earliest indexing year of each database
to April 2019, reporting on the association between dietary flavonoids intake and hypertension.
Results: The search strategy resulted in the final selection of 20 studies including 15 cross-sectional
investigations and 7 prospective cohorts (1 study reported on 3 prospective cohorts). 5 prospective
cohorts, comprising 200,256 individuals and 45,732 cases of hypertension were included in the
quantitative analysis. Analysis by extreme quantiles of intake of flavonoid showed a non-significant
association with decreased risk of hypertension (RR (risk ratio): 0.96, 95% CI (confidence interval):
0.89, 1.03). Taking into consideration individual flavonoid subclasses, dietary anthocyanins intake
was associated with 8% reduction in risk of hypertension, when comparing highest vs. lowest
exposure (RR: 0.92, 95% CI: 0.88, 0.97). Conclusions: Further studies are needed to strengthen
the retrieved association between anthocyanins consumption and decreased risk of hypertension
and clarify whether total flavonoids or rather individual subclasses may exert beneficial effects on
blood pressure.
Keywords: flavonoid; anthocyanin; flavones; hypertension; blood pressure; meta-analysis; cohort
1. Introduction
The reduction in cardiovascular risk and metabolic disorders associated with healthy diets
have been hypothesized to be mediated, among several mechanisms, by their content in
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bioactive phytochemicals possibly endorsed of antioxidant and anti-inflammatory properties [1].
Dietary polyphenols have been recently put under the spotlight due to their wide content in a variety of
commonly consumed foods, and to the findings from numerous studies showing significant evidence
of their association with positive outcomes in the framework of human health [2,3]. Among the most
studied, flavonoids represent the most heterogeneous class in terms of both chemical structure and
bioactivity [4]. This class of polyphenols is characterized by C6–C3–C6 ring structure substituted
with varying numbers of hydroxyl groups. The bioavailability, metabolism, and biological activity
of flavonoids depends on their configuration, total number of hydroxyl groups, substitution or
conjugation of functional groups, and degree of polymerization [5]. The flavonoid class is composed of
several sub-classes, including anthocyanins, isoflavones, flavones, flavonols, flavanones, flavan-3-ols,
and the related oligomeric proanthocyanidins. Each of these sub-classes is contained in a pattern of
different foods, mostly fruits and some vegetables, but also in teas, cocoa, and some alcoholic beverages,
which have been shown to exert beneficial effects toward human health [6–12]. Despite the now
recognized inter- and intra-individual differences in absorption and metabolism, dietary flavonoids
have been considered as potentially responsible, at least in part, for the beneficial effects associated
to plant-based dietary patterns and of many of the benefits attributed to plant-derived beverages,
such as tea and coffee [13,14]. Moreover, the dietary intake of polyphenols has been linked to higher
adherence to a healthy dietary pattern [15], namely the Mediterranean diet, that has been adopted
worldwide [16]. Importantly, different studies showed the association between higher adherence to
Mediterranean pattern, a rich source of flavonoids, and lower prevalence of metabolic features, such as
dyslipidemia [17], obesity [18–22], and hypertension [23,24].
There is a growing interest in the association between dietary flavonoid intake and cardio-metabolic
risk factors. Results from laboratory and clinical investigations have pointed out the potential
benefits of some classes of flavonoids in regulating blood pressure and endothelial function [25–28].
Studies conducted in the context of the PREDIMED (PREvencion con DIeta MEDiterranea) trial
provided mechanistic evidence of association between total polyphenol excretion, blood pressure
levels [29], and plasma nitric oxide production, which is a regulating factor of endothelial function [30].
However, no specific data on flavonoids was provided. Taking into account the documented
heterogeneity in structural characteristics, bioavailability, absorption, and metabolism, it is of interest
to summarize the existing evidence and evaluate which group of compounds provide the most robust
and promising health effect. Thus, the aim of this study was to perform a meta-analysis of prospective
cohort studies investigating the effects of the intake of total and individual subclasses of dietary
flavonoids on the risk of hypertension.
2. Materials and Methods
2.1. Study Selection
A systematic search on electronic databases PubMed (http://www.ncbi.nlm.nih.gov/pubmed/)
and EMBASE (http://www.embase.com/) was performed to retrieve English language studies
published from beginning to April 2019 using the following search terms: (i) flavonoids, flavonols,
flavones, anthocyanidins, flavanones, flavan-3-ols, catechins, isoflavones, proanthocyanidins, quercetin,
myricetin, kaempferol; (ii) lignans, phytoestrogens; (iii) hypertension, blood pressure, cardiovascular,
metabolic; and (iv) cohort, prospective, cross-sectional, longitudinal. Inclusion criteria were
the following: (i) having a prospective design; (ii) evaluating the association between dietary
flavonoids/lignans and/or their classes intake and risk of hypertension; (iii) assessed and reported
hazard ratios (HRs) and the corresponding 95% CI (confidence interval) for hypertension (or sufficient
data to compute them). No specific exclusion criteria were applied besides language restrictions.
Reference lists the studies retrieved were examined to find any additional study potentially unidentified.
If more than one article referred to the same cohort, only the study that included the entire cohort or
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with the longest follow-up was included. The selection process was independently performed by two
authors (G.G. and J.G.) and retrieved articles were examined.
2.2. Data Extraction and Study Quality
Data were extracted from each eligible study by using a standardized extraction form.
The following information was included: (1) first author name; (2) year of publication; (3) cohort name;
(4) country; (5) number of participants (analyzed cohort); (6) sex of participants; (7) age range of the
study population at baseline; (8) dietary food source; (9) sources used to calculate polyphenol intake;
(10) follow-up period; (11) number of cases; (12) distributions of cases and person-years, HRs, and 95%
CIs for all categories of exposure; (13) covariates used in adjustments. This process was independently
performed by two authors (G.G. and J.G.) and discrepancies were discussed and resolved by consensus.
The quality of each study was assessed using the Newcastle-Ottawa Quality Assessment Scale [31].
The scale consists of three variables evaluating the quality of studies, including: selection (4 points),
comparability (2 points), and outcome (3 points) for a total score of 9 points (9 representing the
highest quality).
2.3. Statistical Analysis
Outcomes evaluated in the analyses included occurrence of hypertension. The analyses were
performed for total flavonoid intake as well as for individual classes. HRs with 95% CI for all categories
of exposure were extracted for the analysis. Random-effects models were used in order to estimate
relative risks (RRs) with 95% CIs for the highest versus the lowest category of exposure. The risk
estimate from the most adjusted models were used in the analysis. Heterogeneity was calculated using
the Q test and I2 statistic. The level of significance for the Q test was expressed as p< 0.10. The I2 statistic
represented the amount of total variation that could be attributed to heterogeneity. I2 values ≤25%,
25–50%, 50–75%, and >75% indicated no, small, moderate, and significant heterogeneity, respectively.
A sensitivity analysis by exclusion of one study at the time was performed in order to assess the stability
of results and potential sources of heterogeneity. Additional sensitivity analyses were performed to
test for potential source of heterogeneity by grouping studies according to sex, geographical area,
sample size, length of follow-up, and adjustment for potential confounding factors. Publication bias
was evaluated by a visual investigation of funnel plots for potential asymmetry.
3. Results
3.1. Study Characteristics
The process of identification and study selection is summarized in Figure 1. Among the initial
469 articles screened on the basis of title, 27 articles were screened by reading full-texts. Seven studies
were excluded after a full-text examination for the following reasons: two studies reported insufficient
statistics, four studies reported markers of polyphenol consumption, one study provided the results
only for metabolic syndrome and not hypertension or blood pressure. This search strategy resulted in
the final selection of 20 studies, including 15 cross-sectional investigations and 7 prospective cohorts
(1 study reported on 3 prospective cohorts). Five prospective cohorts, comprising 200,256 individuals
and 45,732 cases of hypertension, were included in the quantitative analysis.
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Figure 1. Process selection of relevant studies reporting on the association between dietary flavonoid
intake and risk of hyperte sion.
Description of main characteristics of the included studies are presented in Table 1. Cross-sectional
studies included several cohorts, including the following: the Mediterranean healthy Eating, Aging,
and Lifestyle (MEAL) study, the WOBASZ study, the Health Survey of Sao Paulo (ISA-Capital Study),
the Framingham Offspring Study, the TOSCA.IT study, the TwinUK registry study, the Tehran Lipid
and Glucose Study (TLGS), the Prospect-EPIC cohort, the Healthy Lifestyle in Europe by Nutrition
in Adolescence (HELENA) study, the Korean National Health and Nutrition Examination Survey
(KNHANES), the Prevención con Dieta Mediterránea (PREDIMED) study, the Alcohol and Psychosocial
factors In Eastern Europe (HAPIEE) and the CARDIA study. Among prospective studies, three cohorts
were conducted in the US, including the Health Professionals’ Follow-up Study (HPFS), the Nurses’
Health Study I (NHS I) and the NHS II [32]; the two cohorts conducted in Europe included the Health,
the Alcohol and Psychosocial factors In Eastern Europe (HAPIEE) study [33] and the E3N, which is the
French component of the European Prospective Investigation into Cancer and Nutrition (EPIC); and
two conducted in Asia included Japan Public Health Center–Based Cohort II (JPHC-II) and Multi-Rural
Communities Cohort (MRCohort) [34]. The cohort size varied between 301 and 87,242 individuals.
Most of the studies included adult individuals ranging 40–70 years’ old. Study quality was consistently
high (Table 1). A total of six studies investigated exposure to total polyphenols including various
classes, six studies focused on flavonoids, two on phenolic acids, and eight studies on phytoestrogens.
Among studies on flavonoid intake, TOT also reported individual subclasses, such as flavonols,
flavones, flavanones, flavan-3-ols, anthocyanins, and oligomers. All studies included covariates that
may have significantly influenced the endpoint outcome (hypertension), such as age, sex (when
not analyzed separately), BMI, education, physical activity, and smoking status; however, not all
studies adjusted for key dietary factors that might influence risk of hypertension, such as sodium and
potassium intake (Table 1).
Estimation of dietary polyphenol intake was performed by using ore frequently the
Phenol-Explorer database, the US Department of Agriculture (USDA) Flavonoid Content of Food
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Database, and the European Food Information Resource (EuroFIR) Bioactive Substances in Food
Information System (eBASIS) database, despite individual studies also used other databases (Table 1).
The main differences across studies regarded the representativeness of the exposed cohort, as the
US cohorts included individuals with demographical (i.e., post-menopausal women or adolescents),
health (i.e., diabetic individuals), and social (i.e., health care workers) characteristics different from
general population.
3.2. Total Polyphenols, Flavonoids, Phenolic Acids, and Blood Pressure/Hypertension
Total polyphenol or individual classes intake was evaluated in five studies. All studies had a
cross-sectional design. In a study investigating major cardiovascular risk factors in a population
of 2573 individuals (aged 50 to 75 years) with type 2 diabetes (the TOSCA.IT study), there was as
significant lower mean systolic and diastolic blood pressure in the highest tertile of total polyphenol,
flavonoids, and phenolic acids intake compared to the lowest one [11]. In another study conducted on
1898 women, aged from 18 to 75 y from the TwinsUK registry, intakes of total flavonoids and their
subclasses (flavanones, anthocyanins, flavan-3-ols, polymers, flavonols, and flavones) were estimated
from validated FFQs using an updated and extended USDA database; among the various groups of
compounds tested, only anthocyanins were linearly associated with systolic blood pressure [35]. In a
pan-european study conducted on adolescents participating to the HELENA study (n = 657) in which
polyphenol intake was assessed through two 24-h recalls and evaluated using the Phenol-Explorer
database, total polyphenol intake was not related with blood pressure, but sub-analyses on polyphenol
classes revealed that flavonoid intake was non-significantly associated with higher diastolic blood
pressure [36]. Finally, a study conducted on 8821 Polish men and women (the HAPIEE study) using a
FFQ and estimation of total/individual polyphenols through the Phenol-Explorer database showed a
linear inverse association between total polyphenol intake and high blood pressure (>130/85 mmHg),
while, among individual classes, a significant inverse association was found with phenolic acid
intake [37].
Among studies conducted outside Europe, an investigation conducted on 2618 Iranian adults,
aged 19 to 84 years, showed that total polyphenol intake (assessed by a FFQ and calculated through the
Phenol-Explorer database) was not related with hypertension, while among various individual classes,
flavonoid intake was linearly inversely associated with systolic and diastolic blood pressure [38].
A study conducted in the context of the ‘Health Survey of Sao Paulo (ISA-Capital)’ among 550 adults
and older adults in Sao Paulo, Brazil assessed total polyphenol intake through two 24-h dietary recalls
reporting an inverse association between the highest tertiles of tyrosols, alkylphenols, lignans, as well
as stilbenes and occurrence of hypertension; however, total polyphenol intake, and phenolic acids
intake was significantly associated only in the middle tertile with hypertension, while association
between flavonoids intake and hypertension was not significant [39].
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Table 1. Characteristics of prospective cohort studies investigating the relation between dietary polyphenol intake and blood pressure/hypertension
Author, Year
Cohort
Name,
Country
Study
Design
Follow-Up
(Years of
Study)
Total
Population
(Analyzed
Sample)
Cases
(Hypertension/High
Blood Pressure)
Sex Age DietaryAssessment
Polyphenol
Estimation Polyphenol Classes
Hypertension
Assessment Adjustments
Vitale, 2006 [11] TOSCA.IT,Italy Cross-sectional NA 2573 NR MF
50–75 y
(range)
248-item
FFQ
USDA and
Phenol-Explorer
database
Flavonoids, phenolic
acids
Blood
pressure
measured
during
clinical visit
Gender, age, BMI, waist and
hip circumferences, smoke,
alcohol intake, dietary lipids,
SFA, MUFA, PUFA, added
sugars, and fiber.
Cassidy, 2011 [32] NHS I, USA Prospective 14 y(1990–2004) 46,672 17,616 F
30–55 y
(range) FFQ
USDA and
EuroFIR
database,
published
literature
Flavonoids (and
subclasses) Self-reported
Age and smoking, BMI, PA,
alcohol consumption, family
history of hypertension,
aspirin use, multivitamin
use, and intakes of sodium,
magnesium, potassium, fiber,
whole grain, folate,
and caffeine.
Cassidy, 2011 [32] NHS II, USA Prospective 14 y(1991–2005) 87,242 11,402 F
25–42 y
(range) FFQ
USDA and
EuroFIR
database,
published
literature
Flavonoids (and
subclasses) Self-reported
Age and smoking, BMI, PA,
alcohol consumption, family
history of hypertension,
aspirin use, multivitamin
use, and intakes of sodium,
magnesium, potassium, fiber,
whole grain, folate,
and caffeine.
Cassidy, 2011 [32] HPFS, USA Prospective 14 y(1990–2004) 23,043 5,629 M
40–75 y
(range) FFQ
USDA and
EuroFIR
database,
published
literature
Flavonoids (and
subclasses) Self-reported
Age and smoking, BMI, PA,
alcohol consumption, family
history of hypertension,
aspirin use, multivitamin
use, and intakes of sodium,
magnesium, potassium, fiber,
whole grain, folate,
and caffeine.
Grosso, 2017 [33] HAPIEE,Poland Prospective
4 y
(2002–2005) 2725 1735 MF
45–69 y
(range)
148-item
FFQ
Phenol-Explorer
database
Total polyphenols,
flavonoids (and
subclasses), phenolic
acids (and
subclasses), stilbenes,
lignans, others
Blood
pressure
measured
during
clinical visit
Age, total energy intake,
BMI, PA, educational status,
smoking status, alcohol
consumption sodium,
potassium and fiber intake,
menopausal status
(women only).
Antioxidants 2019, 8, 152 7 of 21
Table 1. Cont.
Author, Year
Cohort
Name,
Country
Study
Design
Follow-Up
(Years of
Study)
Total
Population
(Analyzed
Sample)
Cases
(Hypertension/High
Blood Pressure)
Sex Age DietaryAssessment
Polyphenol
Estimation Polyphenol Classes
Hypertension
Assessment Adjustments
Lajous, 2016 [34] E3N, France Prospective 14 y(1993–2008) 40,574 9350 F
45–58 y
(range)
208-item
FFQ
Phenol-Explorer
database
Flavonoids (and
subclasses) Self-reported
Education, family history of
hypertension, diabetes,
hypercholesterolemia, BMI,
smoking, PA metabolic
equivalents per week,
hormone therapy, alcohol,
processed meat, caffeine,
magnesium, potassium,
and omega-3.
Jennings, 2012 [35] TwinsUK, UK Cross-sectional NA 1898 NR F 18–75 y(range)
131-item
FFQ
USDA and
Phenol-Explorer
database
Flavonoids (and
subclasses)
Blood
pressure
measured
during
clinical visit
Age, current smoking,
physical activity, BMI, use of
hormone replacement
therapy, use of blood
pressure or statin medication,
use of vitamin supplements,
use of oral contraceptives,
menopausal status, family
history of heart disease or
hypertension, and intakes of
energy, alcohol, SFAs,
MUFAs, PUFAs, fiber,
and sodium.
Wisnuwardani,
2019 [36]
HELENA,
multicenter
Europe
Cross-sectional NA 657 NR MF 12.5–17.5 y(range)
24 h dietary
recalls
Phenol-Explorer
database Total polyphenols
Blood
pressure
measured
during
clinical visit
Age, sex, European region,
education of mother,
education of father, puberty
status, BMI,
monosaccharides and
disaccharides,
polysaccharides, fibre,
monounsaturated fatty acids,
saturated fatty acids,
cholesterol, protein, vitamin
C, and energy intake.
Grosso, 2017 [37] HAPIEE,Poland Cross-sectional NA 8821 5.341 MF
45–69 y
(range)
148-item
FFQ
Phenol-Explorer
database
Total polyphenols,
flavonoids, phenolic
acids, stilbenes,
lignans, others
Blood
pressure
measured
during
clinical visit
Age, gender, education,
physical activity, smoking
status, alcohol drinking,
BMI, and total energy intake.
Sohrab, 2013 [38] TLGS, Iran Cross-sectional NA 2618 NR MF 19–84 y(range)
168-item
FFQ
USDA and
Phenol-Explorer
database
Total polyphenols,
flavonoids, phenolic
acids, stilbenes,
lignans
Blood
pressure
measured
during
clinical visit
Age, gender, physical
activity, smoking status and
educational levels, study
center, and total energy
intake and BMI.
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Table 1. Cont.
Author, Year
Cohort
Name,
Country
Study
Design
Follow-Up
(Years of
Study)
Total
Population
(Analyzed
Sample)
Cases
(Hypertension/High
Blood Pressure)
Sex Age DietaryAssessment
Polyphenol
Estimation Polyphenol Classes
Hypertension
Assessment Adjustments
Miranda, 2016 [39] ISA-CapitalStudy, Brazil Cross-sectional NA 550 267 MF ≥12 y
24 h dietary
recalls
Phenol-Explorer
database
Total polyphenols,
flavonoids, phenolic
acids, stilbenes,
lignans, others (and
subclasses)
Blood
pressure
measured
during
home visit
Age, sex, race, educational
level, BMI, smoking,
physical activity, intake of
sodium, fiber, saturated fat,
alcohol, total energy intake,
misreporting, and other
polyphenol components.
Miranda, 2017 [40] ISA-CapitalStudy, Brazil Cross-sectional NA 557 NR MF
45.1 y
(mean)
24 h dietary
recalls
Phenol-Explorer
database
Coffee polyphenols
(phenolic acids and
others)
Blood
pressure
measured
during
home visit
Age, sex, race, BMI,
smoking, alcohol, physical
activity, household per
capita income, intake of
caffeine, added sugars, total
energy intake, and saturated
fat, other polyphenol intake.
Godos, 2017 [41] MEAL, Italy Cross-sectional NA 1936 976 MF ≥18 y 110-itemFFQ
Phenol-Explorer
database
Phenolic acids (and
subclasses and
individual
polyphenols)
Blood
pressure
measured
during
clinical visit
Age, energy intake, BMI,
smoking status, alcohol
consumption, physical
activity level, educational
level, occupational level,
menopausal status, fiber,
sodium, potassium,
magnesium, and calcium
intake, adherence to the
Mediterranean diet.
Yang, 2012 [42] KNHANES,Korea Cross-sectional NA 4745 NR MF
20–69 y
(range)
24 h dietary
recalls
USDA database,
Japan
Functional
Food Factor
Database, Rural
Development
Administration
Food
Functional
Composition
Table
Flavanols
Blood
pressure
measured
during
clinical visit
Age, BMI, education, current
drinking, vitamin/mineral
supplement use, functional
food use, intakes of total
energy, fat, fiber,
and carbohydrate.
Richardson,
2016 [43]
CARDIA,
USA Cross-sectional NA 3142 843 MF
18–30 y
(range)
100-item
FFQ USDA database Isoflavones
Blood
pressure
measured
during
clinical visit
Age, sex, BMI, smoking,
alcohol intake, physical
activity, total energy,
and sodium intake.
Antioxidants 2019, 8, 152 9 of 21
Table 1. Cont.
Author, Year
Cohort
Name,
Country
Study
Design
Follow-Up
(Years of
Study)
Total
Population
(Analyzed
Sample)
Cases
(Hypertension/High
Blood Pressure)
Sex Age DietaryAssessment
Polyphenol
Estimation Polyphenol Classes
Hypertension
Assessment Adjustments
Godos, 2018 [44] MEAL, Italy Cross-sectional NA 1936 976 MF ≥18 y 110-itemFFQ
Phenol-Explorer
database
Total phytoestrogens,
isoflavones (and
individual
polyphenols), lignans
(and individual
polyphenols)
Blood
pressure
measured
during
clinical visit
Age, energy intake, smoking
status, alcohol consumption,
physical activity level,
educational level,
occupational level, sodium
and potassium intake.
Creus-Cuadros,
2017 [45]
PREDIMED,
Spain Cross-sectional NA 7169 NR MF
~67 y
(mean)
137-item
FFQ
Phenol-Explorer
database Lignans
Blood
pressure
measured
during
clinical visit
Recruitment center, sex, age,
smoking, soft drinks,
carbohydrates, saturated
fatty acids,
monounsaturated fatty acids,
polyunsaturated fatty acids,
n3 fatty acids, and dairies.
Nozue, 2017 [46] JPHC II,Japan Prospective
5 y
(1993–NR) 4165 1335 MF
40–69 y
(range) 52-item FFQ
Published
literature Isoflavones
Blood
pressure
measured
during
clinical visit
Blood pressure at baseline,
age, BMI, alcohol
consumption, smoking
status, physical activity,
energy, energy-adjusted salt,
saturated fats, green and
yellow vegetables, pickled
vegetables, fruits and fish,
public health status,
and menopausal status.
Woo, 2018 [47] MRCohort,South Korea Prospective
3.6 y
(median,
2005–2013)
5509 NR MF ≥40 y 106-itemFFQ USDA database Isoflavones
Blood
pressure
measured
during
clinical visit
Age, calcium intake, fiber
intake, egg consumption in
both men and women, soda
drink consumption for
isoflavones analysis in men
and current smoking, higher
education, regular exercise,
and total energy intake for
soy protein/isoflavones
analyses in women.
de Kleijn, 2002 [48]
Framingham
Offspring
Study, USA
Cross-sectional NA 939 NR F 59 ± 7.5 y(mean)
130-item
FFQ
Published
literature Isoflavones, lignans
Blood
pressure
measured
during
clinical visit
Age, BMI, use of hormone
replacement therapy,
smoking, dietary fiber intake,
and potassium intake.
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Author, Year
Cohort
Name,
Country
Study
Design
Follow-Up
(Years of
Study)
Total
Population
(Analyzed
Sample)
Cases
(Hypertension/High
Blood Pressure)
Sex Age DietaryAssessment
Polyphenol
Estimation Polyphenol Classes
Hypertension
Assessment Adjustments
Kreijkamp-Kaspers,
2004 [49]
Prospect-EPIC,
The
Netherlands
Cross-sectional NA 301 113 F 60–75 y(range) FFQ
Published
literature Isoflavones, lignans
Blood
pressure
measured
during
clinical visit
Age, cholesterol lowering
medication, use of
antihypertensives, BMI,
waist/hip ratio, smoking,
physical activity, total energy
intake, alcohol intake,
saturated fat,
mono-unsaturated fat,
polyunsaturated fat, time
postmenopausal, fiber
intake, fruit intake, vegetable
intake, and vitamin C intake.
Witkowska,
2018 [50]
WOBASZ and
WOBASZ II,
Poland
Cross-sectional NA 2599 1635 F ≥20 y 24 h dietaryrecalls
Published
literature
Lignans (and
individual
polyphenols)
Blood
pressure
measured
during
clinical visit
Age, smoking, BMI, alcohol
intake, education,
leisure-time physical activity,
glucose level, cholesterol
level, menopause hormone
therapy, energy intake.
Abbreviations: CARDIA (Coronary Artery Risk Development in Young Adults); E3N (Etude Epidémiologique auprès des femmes de la Mutuelle Générale de l’Education Nationale); EPIC
(European Prospective Study into Nutrition and Cancer); F (Female); FFQ (Food Frequency Questionnaire); HAPIEE (Health, Alcohol, and Psychosocial factors In Eastern Europe);
HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence); HPFS (Health Professionals Follow-Up Study); JPHC II (Japan Public Health Center–Based Cohort II); KNHANES
(Korean National Health and Nutrition Examination Survey); M (Male); MEAL (Mediterranean healthy Eating, Ageing, and Lifestyle); MRCohort (Multi-Rural Communities Cohort); NA
(Not applicable); NHS I (Nurses’ Health Study I); NHS II (Nurses’ Health Study II); NR (Not Reported); PA (physical activity); PREDIMED (Prevención con Dieta Mediterránea); TGLS
(Tehran Lipid and Glucose Study); USDA (US Department of Agriculture).
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Several studies have been conducted investigating individual classes or single compounds. A study
from the same Brazilian cohort focused the analysis on “coffee polyphenols”, mostly including phenolic
acids: the study showed a significant inverse associations between moderate intake of phenolic acids
(101–337 mg/d) and hypertension [40]. Another study focusing on the relation between phenolic acids and
hypertension was conducted on a sample of southern Italian adults (the MEAL cohort, n = 1937; age 18–92)
in which polyphenol intake was assessed by a validated FFQ and calculated through the Phenol-Explorer
database; individuals in the highest quartile of phenolic acid intake (median intake = 522.2 mg/day)
were less likely to have hypertension, while when considering individual subclasses of phenolic acids,
only hydroxyphenylacetic acids were inversely associated with hypertension [41]. Among the studies
focusing the attention on one single class (or subclass) of polyphenols, an investigation conducted on
1827 men and 2918 women aged 20–69 years living in Korea (the KNHANES survey) calculated the intake
of flavanols from 24-h dietary recalls using various databases on polyphenol content in foods (including
the USDA Flavonoid Content of Food Database, the Japan Functional Food Factor Database, and the
Rural Development Administration Food Functional Composition Table) reporting an inverse association
with high blood pressure (defined as systolic blood pressure ≥130 mmHg and diastolic blood pressure
≥85 mmHg) in women but not in men [42].
3.3. Phytoestrogens and Blood Pressure/Hypertension
A total of eight studies investigated the association between total or individual phytoestrogen intake
and blood pressure or occurrence of hypertension. A study recruiting African American and Caucasian
men and women aged 18 to 30 years at baseline and following them up to 20 years; the authors reported
that in multivariate adjusted models, the highest quartile of dietary isoflavone intake was associated with a
4.4 mm Hg lower SBP when compared with SBP for the lowest quartile [43]. Among studies conducted in
individuals living in the Mediterranean area, participants of the MEAL cohort in the highest quartile of
total phytoestrogens intake were less likely to be hypertensive, while no significant results were found
for isoflavones and lignans separately; however, some individual compounds, such as biochanin A and
pinoresinol showed an independent inverse association with hypertension [44]. Another study conducted
in elderly individuals living in the Mediterranean area included participants of the PREDIMED trial,
which showed no relation between lignan intake (estimated by Phenol-Explorer database) and blood
pressure, while a significant inverse association was found when considering lignan intake together with
low-fat dairy products [45]. Among studies conducted in Asian countries, where the major sources of
phytoestrogens are soy products, participants of the JPHC-II (926 men and 3239 women) were examined
through a FFQ including questions on soy consumption and isoflavone intake estimated with the use of
Standard Tables of Food Composition in Japan, and development of high blood pressure, defined as systolic
blood pressure >130 mm Hg or diastolic blood pressure >85 mm Hg or antihypertensive medication use;
the study showed that isoflavones from total soy products was associated with lower risk of high blood
pressure in women but not in men, while isoflavones from fermented soy product was associated in men
but not in women [46]. Another study conducted on Korean men and women (n = 5509) aged more
than 40 years old testing the association between soy isoflvones (calculated based on a database for foods
consumed by Koreans and the USDA database) and high blood pressure (>130/85 mmHg) showed an
inverse relation in both men and women, despite a linear association being observed only in women but
not in men [47].
Given the weak estrogenic effects of phytoestrogens, some studies have been conducted focusing
on post-menopausal women, which may sensibly benefit of such effect. A study conducted on
939 postmenopausal women participating in the Framingham Offspring Study aimed to assess the
relation between phytoestrogen intake (assessed through self-administered FFQ and calculated by
literature review) and cardiovascular risk factors, showed no significant differences between mean
systolic and diastolic blood pressure across quartiles of isoflavones and lignans intake [48]. In another
study conducted on 301 postmenopausal women (aged 60–75 years) living in The Netherlands exploring
dietary phytoestrogen intake assessed using a FFQ covering the year prior to enrolment, no associations
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were found for higher intake of isoflavones and systolic and diastolic blood pressures, while it
was observed lower systolic and diastolic blood pressures and a lower prevalence of hypertension
associated with higher lignans intake [49]. Finally, a study conducted on post-menopausal Polish
women participating to the WOBASZ and WOBASZ II surveys (n= 2599) assessing dietary lignans intake
using a single 24-h recall and the Dutch lignan database (together with other various sources derived
from the literature) reported no relation of total and individual lignans and having hypertension [50].
3.4. Quantitative Meta-Analysis for Dietary Flavonoid Intake and Risk of Hypertension
Comparable data to perform meta-analysis of risk estimates was available only for prospective
studies exploring the relation between dietary flavonoid (including all subclasses of flavonoids) intake
and risk of hypertension. Forest plots comparing the highest versus the lowest intake of flavonoid
intake (total and subclasses) and risk of hypertension are shown in Figure 2.Antioxida ts 2019, 8, x; doi: FOR PEER REVIEW  14 of 22 
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The analysis showed a non-significant association with decreased risk of hypertension (RR: 0.96,
95% CI: 0.89, 1.03; Figure 2) with significant heterogeneity (I2 = 74%, Pheterogeneity = 0.01), but no
evidence of publication bias (Supplementary Figure S1). Exclusion of one study at the time revealed
that significant results could be retrieved when not considering the HPFS cohort, despite the exclusion
not reducing heterogeneity between remaining studies. A sensitivity analysis of subgroups defined
by variables that may be responsible for heterogeneity showed significant results when considering
only women and studies conducted in Europe, while no further evidence was found when considering
studies with larger samples and longer follow-up (Table 2).
Table 2. Subgroup analyses of studies reporting risk of hypertension for the highest versus lowest
(reference) category of dietary flavonoids
Subgroup/Additional Analysis No. of Cohorts RR (95% CI) I2 Pheterogeneity
Total 5 0.96 (0.89, 1.03) 74% 0.002
Sex
Male 2 1.06 (0.97, 1.16) 0% 0.87
Female 4 0.93 (0.87, 1.00) 76% 0.005
Geographical area
Europe 2 0.88 (0.83, 0.93) 0% 0.37
North America 3 0.99 (0.93, 1.07) 73% 0.02
Number of cases
>10,000 2 0.97 (0.91, 1.04) 72% 0.06
<10,000 3 0.93 (0.79, 1.10) 79% 0.003
Follow-up
>10y 4 0.97 (0.90, 1.04) 82% 0.0009
<10y 1 0.78 (0.50, 1.21) 31% 0.23
Adjusted for smoking
No 0 NA NA NA
Yes 5 0.96 (0.89, 1.03) 74% 0.002
Adjusted for potassium/sodium
No 0 NA NA NA
Yes 5 0.96 (0.89, 1.03) 74% 0.002
Adjusted for physical activity
No 0 NA NA NA
Yes 5 0.96 (0.89, 1.03) 74% 0.002
Adjusted for BMI
No 0 NA NA NA
Yes 5 0.96 (0.89, 1.03) 74% 0.002
Adjusted for education
No 3 0.99 (0.93, 1.07) 73% 0.02
Yes 2 0.88 (0.83, 0.93) 0% 0.37
The analysis of individual flavonoid subclasses showed significant association with hypertension
risk reduction for higher intake anthocyanins with no evidence of significant heterogeneity and no
evidence of publication bias at funnel plot (Supplementary Figure S1) whereas no association for
extreme categories of exposure of flavonols, flavones, flavanones, and flavan-3-ols, was found (Figure 2).
Sensitivity analysis conducted by excluding one study at a time revealed that also flavones were
significantly associated with decreased risk of hypertension after exclusion of the HPFS cohort (with no
significant heterogeneity and no evidence of publication bias) while all other results remained stably
not significant.
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4. Discussion
In this systematic review and meta-analysis, we reviewed existing studies on dietary polyphenols
and blood pressure in epidemiological studies and investigated the association between total
or individual subclasses of flavonoid intake and risk of hypertension in prospective cohort
studies. The epidemiological studies evaluating the association between total dietary polyphenols
and cardio-metabolic risk factors, including hypertension, generally showed contrasting results.
Among articles with cross-sectional design, while no study but one [38] reported an inverse association
between total polyphenol or flavonoid intake and occurrence of hypertension, few studies reported
significant results for phenolic acids [40,41]. The findings on the relation between dietary phytoestrogens
intake and blood pressure are more univocal, with general significant inverse association between intake
of either isoflavones or lignans and blood pressure levels, despite heterogeneity of results between
sexes and the cross-sectional design of most of the studies reviewed limiting the level of evidence.
Among subclasses of flavonoids, the meta-analysis showed that dietary intake of anthocyanins was
significantly associated with reduced risk of hypertension: comparison of the highest vs. lowest
anthocyanins exposure showed an 8% reduction in risk of hypertension. Moreover, after exclusion
of data from one cohort, also the analyses for total flavonoids and flavones demonstrated significant
results. Significant heterogeneity between studies observed for total flavonoids should be considered as
a major limitation of these findings. Nevertheless, heterogeneity was mainly related to the strength of
the association rather than to the direction of risk estimates, suggesting overall promising perspectives
for future studies.
Existing literature on studies aiming to explore the relation between flavonoid-rich foods, dietary
flavonoids and hypertension is generally consistent but not univocal. Two meta-analyses of dietary
interventions characterized by isocaloric diets with pulses or fruits and vegetables (including one
portion of berries/day and 50 g of dark chocolate) showed significant reduction in systolic/diastolic
blood pressure [51] and of markers of endothelial function [52], respectively. Among major food
sources of anthocyanins, potential blood pressure lowering effects have been demonstrated for
pomegranate juice [53] and berries [54,55], whereas a lack of effects has been reported for blueberry
supplementation [56]. Among food sources of isoflavones, a meta-analysis exploring the effects of
soybeans on blood pressure in postmenopausal women showed that ingestion of ≥25 g soy protein
per day had blood pressure-lowering effects, and the improvements in blood pressure may be
due to the isoflavones component of soy protein [57]. Other sources of phytoestrogens are seeds,
which are rich in lignans: meta-analyses on clinical trials evaluating the effects of flaxseeds and
sesame consumption on blood pressure concluded that they both may exert blood pressure-lowering
effects [58,59]. Among the major sources of phenolic acids, the most comprehensive meta-analysis of
cohort studies on coffee consumption and incidence of new-onset hypertension reported a modest
decrease in risk of hypertension [60], while several meta-analyses investigating the effects of tea on
blood pressure, showing potential benefits for long-term (>12 weeks) intake [61,62] and significant
effects also for secondary prevention of cardiovascular disease among overweight and obese adults [63]
and in individuals within pre-hypertensive and hypertensive ranges [64]. However, meta-analysis of
clinical trials on polyphenol supplementation showed contrasting results. A previous meta-analysis of
randomized controlled trials on the effects of anthocyanins on blood pressure showed overall null
results [65]. Other meta-analyses on soy isoflavones supplementation reported that soy isoflavone
extracts significantly decreased systolic but not diastolic blood pressure in adult humans, and no
dose–response relationship was observed [66], while another meta-analysis suggested that the effects
were more evident in hypertensive, but not in normotensive individuals [67]. Similarly, the beneficial
potential of flaxseed to reduce blood pressure may be greater when it is consumed as a whole seed
rather than as lignan extract [68]. Possible reasons for such scarce findings may depend on limitations
in the study design of the trials included in the analysis, or on the short-term consumption to which
the trials refer, which may be indicative of potential acute effects, but not equivalent to long term
consumption. Moreover, supplementation using pharmaceutical formulas (i.e., pills or capsules) of
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pure extracts may not be equivalent to dietary intake. Finally, it has been suggested that flavonoid
bioactivity may not follow a classical linear dose–response association, and attention should be payed
when designing and pooling together results from randomized controlled trials [69].
Flavonoids have been hypothesized to exert beneficial effects towards the cardiovascular
system through their antioxidant and antiradical action, exerted through a variety of molecular
mechanisms [70], and importantly, as demonstrated in both experimental and clinical studies, altered
oxidative imbalance is linked to higher cardiovascular risk [71–74]. Furthermore, flavonoids may
also act more specifically as signaling molecules, interacting with cellular receptors or proteins
that are involved in regulatory pathways, resulting in physiological responses or regulation of
gene expression [70]. Regarding their potential effects on endothelial function and regulation of
vasodilatory processes associated with blood-flow, flavonoids can act as inhibitors of endothelial
NAD(P)H oxidase, which has been linked to the regulation of nitric oxide (NO) levels in the vascular
endothelium via inhibition of superoxide production [75]. Specific classes of phenolic compounds or
their metabolites have been reported to improve endothelial dysfunction through their antioxidant
attitude, but also directly acting over NO metabolism or reducing vasoconstriction by acting on ACE
and angiotensin II receptor activity [76]. In particular, isoflavones have demonstrated interaction
with the estrogen-response element of genes related to endothelial NO synthase leading to increase
in endogenous NO production [77]. Furthermore, in several studies, flavonoids were shown to
modulate inflammation through inflammatory cell infiltration, lowered levels of pro-inflammatory
cytokines, and improved cell survival and function. These anti-inflammatory effects were mediated
via inhibition of NF-κB [78,79]. Concerning anthocyanins, the only subclass of flavonoids that was
significantly associated with decreased risk of hypertension in the present study, their effects involve
targeting the NF-κB signaling pathway, activator protein 1(AP-1), the Phase II enzyme activation and
Nrf2, and the mitogen-activated protein kinase (MAPK) signaling pathway [80]. Anthocyanins were
shown to exert inhibitory action against vasodilators. In example, blackberry juice containing
cyanidin-3-O-glucoside was shown to exert protective effects against endothelial dysfunction and
vascular failure via scavenging of peroxynitrate, a strong oxidant responsible for DNA and protein
damage [81]. In line with those results, another study demonstrated that anthocyanin fraction of
blackberry extract was able to suppress NO production via inhibition of inducible NO synthase due to
the attenuation of NK-κB and MAPK signaling pathways [82]. Cyanidin-3-O-glucoside was shown to
regulate the phosphorylation of endothelial NO synthase, thus ameliorating endothelial dysfunction
and regulating blood pressure [83,84]. Finally, delphinidin, an anthocyanin present in red wine,
was demonstrated to inhibit endothelial cell apoptosis via NO pathway and regulation of calcium
homeostasis [85]. However, when taking into account the results obtained for anthocyanins, it should
be considered that anthocyanins are relatively unstable molecules, as they undergo re-arrangements
in response to pH. Depending on the nature of compound and sugar conjugation, anthocyanins
were shown to reach the human colon after ingestion [86]. Despite laboratory studies providing the
biological rationale for the potential association of dietary flavonoids and, in particular, anthocyanins
and risk of hypertension, the overall results need to be further clarified by additional experimental and
epidemiological studies.
Some limitations of the included studies may explain the retrieved heterogeneity of results and
the lack of significance of certain analyses. First, differences in polyphenol food content databases used
among studies may lead to different ‘weighting’ of food items selected in terms of flavonoid content.
Moreover, only some compounds are known to exert beneficial effects toward the endothelium [87],
and intra- and inter-individual differences in absorption and metabolism of such compounds may
enhance or reduce such activity. Secondly, food items included in dietary questionnaires comprised
different numbers of foods containing flavonoids, thus further potentially biasing the real content
of polyphenols. Additionally, studies with only baseline evaluation of food intake may not have
taken into account possible changes of the diet over the follow-up period. However, as the exposure
was ascertained before the diagnosis of hypertension, misclassification would tend to underestimate
Antioxidants 2019, 8, 152 16 of 21
the true associations. Moreover, the role of individual dietary compounds is difficult to disentangle,
as intake of polyphenols has been reported to correlate with the intake of fruits and vegetables and their
constituents—i.e., vitamin C, vitamin E, carotenoids, folate, and fiber—which may confound or act
synergistically toward the risk of chronic diseases [88]. Finally, subgroup analyses showed significant
results only among women. A possible explanation for this is the natural differences occurring between
men and women due to hormonal protection in the latter before menopause. However, these potential
differences need to be further investigated.
5. Conclusions
In conclusion, results from this study are promising but not conclusive. Further studies are
needed to elucidate the retrieved association between polyphenol consumption and decreased risk of
hypertension and to clarify whether individual subclasses, rather than the total content of polyphenols,
may exert beneficial effects on blood pressure.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3921/8/6/152/s1,
Figure S1: Funnel plot for hypertension risk of the highest versus lowest (reference) category of dietary flavonoid
intake, Table S1: PRISMA checklist.
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